) recently announced that the company has regained global rights
for the development and commercialization of compounds, which are
covered under its AKT collaboration with Daiichi Sankyo Co.,
The compounds include candidate ARQ 092, which is currently in
a phase I trial. We note that Daiichi Sankyo and ArQule entered
into a license agreement for the development of ARQ 092 in Nov
As per the license agreement, Daiichi Sankyo had exclusive
rights for the development, manufacturing and marketing of ARQ
092 on a global basis. In exchange, ArQule received a $10 million
upfront payment from Daiichi Sankyo in Nov 2011 along with
support for the ongoing phase I trial on ARQ 092.
ArQule gained back its rights to the AKT program and to ARQ
092 after Daiichi Sankyo decided to terminate the license and
ARQ 092 is a selective AKT inhibitor, which was invented from
the proprietary ArQule Kinase Inhibitor Platform (AKIP). ArQule
uses AKIP technology to design and develop cancer drugs.
Apart from ARQ 092, ArQule's pipeline also includes oncology
candidate ARQ 197 (tivantinib).
In Jan 2013, ArQule and partner Daiichi Sankyo initiated a
phase III METIV-HCC -- MET-high patients with tivantinib in
hepatocellular carcinoma (HCC) -- trial on ARQ 197.
The study is evaluating the candidate for the treatment of
patients suffering from HCC who have previously received one or
two prior systemic anti-cancer therapies. The primary endpoint of
the trial is overall survival (OS) while the secondary endpoint
is progression-free survival.
ArQule currently carries a Zacks Rank #3 (Hold). Pharma stocks
that currently look well placed are
Furiex Pharmaceuticals Inc
ARQULE INC (ARQL): Free Stock Analysis Report
AVANIR PHARM (AVNR): Free Stock Analysis
BIODEL INC (BIOD): Free Stock Analysis Report
FURIEX PHARMACT (FURX): Free Stock Analysis
To read this article on Zacks.com click here.